Back to Newsroom

Pharnext’s PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting

PARIS, June 30, 2015, Pharnext SAS today announced that data related to its lead pleodrug PXT-3003, being developed for the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented in four posters and one oral session at the 2015 Peripheral Nerve Society (PNS) Biennial Meeting at the Quebec Congress Center in Quebec City, Canada, June 27 – July 2, 2015.

Click here to read more